Literature DB >> 24882621

Serum apolipoprotein B-48 concentration is associated with a reduced estimated glomerular filtration rate and increased proteinuria.

Manabu Okubo1, Hiroyuki Hanada, Masahiko Matsui, Yoh Hidaka, Daisaku Masuda, Yasushi Sakata, Shizuya Yamashita.   

Abstract

AIM: Apolipoprotein B-48 (apoB-48) is a constituent of chylomicrons and their remnants (chylomicron remnants). A high concentration of serum apoB-48 is suspected to be a major risk factor for the development of atherosclerotic cardiovascular disease. Proteinuria and a reduced estimated glomerular filtration rate (eGFR) are independent risk factors for cardiovascular events and renal dysfunction. In the present study, we examined whether the serum apoB-48 concentration is associated with renal dysfunction.
METHODS: A total of 264 patients was enrolled and classified into four groups according to the eGFR and level of proteinuria: a high eGFR (>60mL/min/1.73m(2)) without proteinuria (≥1+ by urine dipstick) (n=50); a high eGFR with proteinuria (n=75); a low eGFR (>60mL/min/1.73m(2)) without proteinuria (n=74); and a low eGFR with proteinuria (n=65). Biochemical markers of lipid metabolism, including the fasting serum apoB-48 concentration, were compared between the four groups.
RESULTS: The serum log-apoB-48 and log-apoB-48/TG levels were significantly higher in the patients with a high eGFR with proteinuria, low eGFR with proteinuria and low eGFR without proteinuria than in those with a high eGFR without proteinuria, with the most significant differences for these parameters. The eGFR was found to be significantly correlated with the log-apoB-48 and log-apoB-48/TG levels, whereas urinary protein was found to be significantly correlated with the log-apoB-48 level only. A multiple regression analysis indicated that the log-apoB-48/TG level was a significant determinant of a reduced eGFR.
CONCLUSIONS: Both a low eGFR (<60) and proteinuria (≥1+) are independent determinants of a high apoB-48 concentration. Taken together, the present results suggest that an increased serum apoB-48 concentration contributes to an increased risk of cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24882621     DOI: 10.5551/jat.23309

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  3 in total

Review 1.  Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.

Authors:  Nans Florens; Catherine Calzada; Egor Lyasko; Laurent Juillard; Christophe O Soulage
Journal:  Toxins (Basel)       Date:  2016-12-16       Impact factor: 4.546

2.  Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study.

Authors:  Shinichi Oikawa; Shizuya Yamashita; Noriaki Nakaya; Jun Sasaki; Suminori Kono
Journal:  J Atheroscler Thromb       Date:  2016-07-08       Impact factor: 4.928

Review 3.  Postprandial Hyperlipidemia and Remnant Lipoproteins.

Authors:  Daisaku Masuda; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2016-11-08       Impact factor: 4.928

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.